Ipilimumab was approved based on the results from the phase 3 randomised trial (MDX010-20) including a total of 676 patients with unresectable stage III or IV melanoma who were randomly assigned in a 3:1:1 ratio to receive ipilimumab plus gp100, ipilimumab alone, or gp100 alone [32]. This evidence concerns the gene PMEL and melanoma.